TARRYTOWN, New York, May 15, 2026
Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the combination of fianlimab, an investigational LAG-3 inhibitor, with cemiplimab, a PD-1 inhibitor, as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma. While the study showed a numerical improvement in progression-free survival (PFS) compared with pembrolizumab monotherapy, the trial did not achieve statistical significance for its primary endpoint, representing a setback for Regeneron’s effort to expand its immuno-oncology portfolio in advanced melanoma treatment.
High-Dose Fianlimab Combination Shows Numerical PFS Benefit
The randomized, double-blind Phase 3 study enrolled 1,546 patients aged 12 years and older who had not previously received systemic treatment for advanced melanoma. Patients were assigned to receive either a high-dose fianlimab plus cemiplimab combination, a lower-dose version of the combination, pembrolizumab monotherapy, or cemiplimab monotherapy.
Results showed the high-dose fianlimab combination achieved a median progression-free survival of 11.5 months, compared with 6.4 months for pembrolizumab monotherapy, representing a 5.1-month numerical improvement. However, the study narrowly missed statistical significance with a hazard ratio of 0.845 and a p-value of 0.0627. The low-dose combination produced a median PFS of 9.6 months, but also failed to demonstrate statistical significance versus pembrolizumab.
Importantly, Regeneron stated that no new safety signals were identified during the study, supporting the overall tolerability profile of the combination therapy. The company plans to present detailed data from the trial at an upcoming medical conference.
Ongoing Head-to-Head Trial Against Opdualag Continues
Advertisement
Despite the missed primary endpoint, Regeneron continues development of the high-dose combination in a separate ongoing Phase 3 head-to-head trial against Opdualag®, the approved Bristol Myers Squibb combination therapy consisting of nivolumab and relatlimab-rmbw. That study is also focused on patients with previously untreated unresectable or metastatic melanoma.
The results highlight the increasing competition in the rapidly evolving LAG-3 inhibitor market, where companies are exploring combinations of immune checkpoint inhibitors to improve outcomes for advanced cancer patients. Although the trial outcome may limit immediate regulatory momentum for the fianlimab-cemiplimab regimen, the observed numerical improvement in PFS suggests the therapy could still demonstrate clinical value in future analyses or comparative studies.
Melanoma Immunotherapy Market Remains Highly Competitive
Melanoma remains one of the most aggressive forms of skin cancer, and immunotherapy combinations targeting immune checkpoint pathways such as PD-1 and LAG-3 have become a major area of oncology drug development. The approval of therapies like Opdualag validated LAG-3 as an important therapeutic target, increasing pressure on competing drug developers to demonstrate superior efficacy and safety profiles.
Regeneron emphasized that both fianlimab and cemiplimab remain investigational in this combination setting, and their safety and efficacy have not yet been evaluated by regulatory authorities for this indication. The company continues to invest heavily in oncology research, leveraging its antibody development platforms and immunotherapy pipeline to expand treatment options for cancer patients worldwide.
The trial outcome is likely to be closely watched by investors, oncologists, and biopharma competitors as the industry evaluates the commercial and clinical future of next-generation melanoma immunotherapies.
Source: Regeneron Pharmaceuticals press release
